0001493152-23-024786.txt : 20230718
0001493152-23-024786.hdr.sgml : 20230718
20230718090021
ACCESSION NUMBER: 0001493152-23-024786
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230710
FILED AS OF DATE: 20230718
DATE AS OF CHANGE: 20230718
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GILLIS STEVEN
CENTRAL INDEX KEY: 0001229592
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37769
FILM NUMBER: 231093107
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VBI Vaccines Inc/BC
CENTRAL INDEX KEY: 0000764195
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 160 SECOND STREET
STREET 2: CAMBRIDGE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-830-3031
MAIL ADDRESS:
STREET 1: 160 SECOND STREET
STREET 2: CAMBRIDGE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: SciVac Therapeutics Inc.
DATE OF NAME CHANGE: 20150717
FORMER COMPANY:
FORMER CONFORMED NAME: LEVON RESOURCES LTD.
DATE OF NAME CHANGE: 20100910
FORMER COMPANY:
FORMER CONFORMED NAME: LEVON RESOURCES LTD
DATE OF NAME CHANGE: 19850305
4
1
ownership.xml
X0508
4
2023-07-10
0
0000764195
VBI Vaccines Inc/BC
VBIV
0001229592
GILLIS STEVEN
C/O VBI VACCINES INC.,
160 SECOND STREET, FLOOR 3
CAMBRIDGE
MA
02421
1
0
0
0
0
Common Shares, no par value per share
2814
D
Common Shares, no par value per share
2023-07-10
4
P
0
609090
1.65
A
1043292
I
See Footnotes
Warrant (right to buy)
1.65
2023-07-10
4
P
0
609090
D
2023-07-10
2028-07-10
Common Shares
609090
609090
I
See Footnotes
Includes 100,869 common shares held of record by ARCH Venture Fund VI, L.P. ("ARCH VI") and 942,423 common shares held of record by ARCH Venture Fund X Overage, L.P. (the "ARCH Overage"). ARCH Venture Partners VI, L.P. (the "ARCH GPLP"), as the sole general partner of ARCH VI, may be deemed to beneficially own certain of the shares held of record by ARCH VI. The ARCH GPLP disclaims beneficial ownership of all shares held of record by ARCH VI in which the ARCH GPLP does not have an actual pecuniary interest. ARCH Venture Partners VI, LLC (the "ARCH GPLLC"), as the sole general partner of the ARCH GPLP, may be deemed to beneficially own certain of the shares held of record by ARCH VI. The ARCH GPLLC disclaims beneficial ownership of all shares held of record by ARCH GPLP in which the ARCH GPLLC does not have an actual pecuniary interest.
ARCH Venture Partners X Overage, L.P. (the "Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own certain of the shares held of record by ARCH Overage. The Overage GPLP disclaims beneficial ownership of all shares held of record by ARCH Overage in which the Overage GPLP does not have an actual pecuniary interest. ARCH Venture Partners X, LLC (the "Overage GPLLC"), as the sole general partner of the Overage GPLP, may be deemed to beneficially own certain of the shares held of record by ARCH Overage. The Overage GPLLC disclaims beneficial ownership of all shares held of record by Overage GPLP in which the Overage GPLLC does not have an actual pecuniary interest.
The reporting person owns an interest in ARCH GPLP but does not have voting or investment control over the shares held by ARCH VI, and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The reporting person owns an interest in Overage GPLP and may be deemed to have voting and investment control over the shares held by ARCH Overage as member of the investment committee of Overage GPLLC, but disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The 609,090 common shares reported in Table I and accompanying warrants to purchase up to 609,090 common shares reported in Table II of this Form 4 were purchased together at a combined public offering price of $1.65 per share and accompanying warrant, which such combined public offering price included $0.01 per accompanying warrant.
/s/ Steven Gillis
2023-07-17